Cited 4 times in
Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구교철 | - |
dc.contributor.author | 나군호 | - |
dc.contributor.author | 박상언 | - |
dc.contributor.author | 양승철 | - |
dc.contributor.author | 정병하 | - |
dc.contributor.author | 홍성준 | - |
dc.contributor.author | 홍창희 | - |
dc.date.accessioned | 2016-02-04T11:48:07Z | - |
dc.date.available | 2016-02-04T11:48:07Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141234 | - |
dc.description.abstract | OBJECTIVE: To investigate whether transurethral resection of the prostate can be used as both (i) treatment for symptomatic prostatic enlargement in patients with prostate cancer and (ii) a risk-adaptive strategy for reducing prostate-specific antigen levels and broadening the indications of active surveillance. METHODS: We retrospectively reviewed data of 3680 patients who underwent prostate biopsies at a single institution (March 2006 to January 2012). Of 529 men who had Gleason score 6 prostate cancer and were ineligible for active surveillance, 86 (16.3%) underwent transurethral resection of the prostate for symptomatic prostatic enlargement. We assessed how changes in prostate-specific antigen and prostate-specific antigen density influenced the eligibility for active surveillance and the outcome of subsequent therapy. The following active surveillance criteria were used: prostate-specific antigen ≤ 10 ng/ml, prostate-specific antigen density ≤ 0.15, positive cores ≤ 3 and single core involvement ≤ 50%. RESULTS: The median age, pre-operative prostate-specific antigen and prostate volume were 71 years, 6.95 ng/ml, and 45.8 g, respectively. In 82.6% (71/86) of analyzed cases, ineligibility for active surveillance had resulted from elevated prostate-specific antigen level or prostate-specific antigen density. With a median resection of 16.5 g, transurethral resection of the prostate reduced the percentage of prostate-specific antigen and the percentage of prostate-specific antigen density by 34.5 and 50.0%, respectively, making 81.7% (58/71) of the patients eligible for active surveillance. Prostate-specific antigen level remained stabilized in all (21/21) patients maintained on active surveillance without disease progression during the median follow-up of 50.6 months. Among patients who underwent radical prostatectomy, 96.7% (29/30) exhibited localized disease. CONCLUSIONS: Risk-adaptive transurethral resection of the prostate may prevent overtreatment and allay prostate-specific antigen-associated anxiety in patients with biopsy-proven low-grade prostate cancer and elevated prostate-specific antigen. Additional benefits include voiding symptom improvement and the avoidance of curative therapy's immediate side effects. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 785~790 | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers, Tumor/blood* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Grading | - |
dc.subject.MESH | Population Surveillance*/methods | - |
dc.subject.MESH | Prostate-Specific Antigen/blood* | - |
dc.subject.MESH | Prostatic Neoplasms/blood | - |
dc.subject.MESH | Prostatic Neoplasms/complications | - |
dc.subject.MESH | Prostatic Neoplasms/pathology* | - |
dc.subject.MESH | Prostatic Neoplasms/surgery* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Transurethral Resection of Prostate* | - |
dc.title | Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨기과학) | - |
dc.contributor.googleauthor | Kyo Chul Koo | - |
dc.contributor.googleauthor | Sang Un Park | - |
dc.contributor.googleauthor | Koon Ho Rha | - |
dc.contributor.googleauthor | Sung Joon Hong | - |
dc.contributor.googleauthor | Seung Choul Yang | - |
dc.contributor.googleauthor | Chang Hee Hong | - |
dc.contributor.googleauthor | Byung Ha Chung | - |
dc.identifier.doi | 10.1093/jjco/hyv073 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00188 | - |
dc.contributor.localId | A01227 | - |
dc.contributor.localId | A01486 | - |
dc.contributor.localId | A02294 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A04402 | - |
dc.contributor.localId | A04447 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 25979243 | - |
dc.identifier.url | http://jjco.oxfordjournals.org/content/45/8/785.long | - |
dc.subject.keyword | prostate cancer | - |
dc.subject.keyword | prostate-specific antigen | - |
dc.subject.keyword | surveillance | - |
dc.subject.keyword | transurethral resection of prostate | - |
dc.contributor.alternativeName | Koo, Kyo Chul | - |
dc.contributor.alternativeName | Rha, Koon Ho | - |
dc.contributor.alternativeName | Park, Sang Un | - |
dc.contributor.alternativeName | Yang, Seung Choul | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.alternativeName | Hong, Sung Joon | - |
dc.contributor.alternativeName | Hong, Chang Hee | - |
dc.contributor.affiliatedAuthor | Koo, Kyo Chul | - |
dc.contributor.affiliatedAuthor | Rha, Koon Ho | - |
dc.contributor.affiliatedAuthor | Park, Sang Un | - |
dc.contributor.affiliatedAuthor | Yang, Seung Choul | - |
dc.contributor.affiliatedAuthor | Chung, Byung Ha | - |
dc.contributor.affiliatedAuthor | Hong, Sung Joon | - |
dc.contributor.affiliatedAuthor | Hong, Chang Hee | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 45 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 785 | - |
dc.citation.endPage | 790 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.45(8) : 785-790, 2015 | - |
dc.identifier.rimsid | 31427 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.